Premium
A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non‐small cell lung cancer
Author(s) -
GOKSEL Tuncay,
HATIPOGLU Osman Nuri,
OZTURK Can,
GORGUNER Metin,
KIYIK Murat,
YILMAZ Ugur,
GUZELANT Asuman,
TASBAKAN Sezai,
TABAKOGLU Erhan,
FIRAT Hikmet,
TUTAR Umit,
CIKRIKICIOGLU Sadettin,
AKKOCLU Atila,
SOYER Serdar,
CAKIR Ebru,
ITIL Oya,
SANAL Salahattin
Publication year - 2005
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/j.1440-1843.2005.00739.x
Subject(s) - medicine , gemcitabine , neutropenia , etoposide , lung cancer , cisplatin , regimen , chemotherapy , gastroenterology , survival rate , oncology
Objective: Cisplatin‐gemcitabine (PG) and cisplatin‐etoposide (PE) combinations are active regimens for non‐small cell lung cancer (NSCLC). The present study aimed to compare PG with PE in the treatment of patients with stage IIIB and IV NSCLC. Methodology: We conducted a prospective, multicentre trial. A total of 166 patients were enrolled into the study and received either gemcitabine (1000 mg/m 2 ) on days 1, 8 and 15 plus cisplatin (80 mg/m 2 ) on day 2 every 4 weeks, or etoposide (100 mg/m 2 ) on days 1, 2 and 3 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks. Results: The overall response rate was superior in the PG group (54.8% vs 39.0%, P = 0.045). There was no significant difference in survival between the two groups, with respective median and 1‐year survival of 38 weeks and 33.3% for the PG group, and 34 weeks and 23.2% for the PE group. There was also no statistical difference for time to progression between the two groups. Neutropenia and thrombocytopenia were seen more frequently in the PG group (grade 3 neutropenia, 33.3% vs 15.9%, P = 0.012; grade 3 thrombocytopenia, 27.4% vs 3.7%, P < 0.001 and grade 4 thrombocytopenia, 10.7% vs 1.2%, P = 0.018). Conclusion: PG is an active chemotherapy regimen and has a better response rate than PE in advanced NSCLC, although there was no difference in time to progression and overall survival. A higher incidence of haematological toxicity was seen with PG than with PE.